Health Catalyst (NASDAQ:HCAT) Given New $2.00 Price Target at Stifel Nicolaus

Health Catalyst (NASDAQ:HCAT) had its target price lowered by stock analysts at Stifel Nicolaus from $3.75 to $2.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 46.84% from the company’s current price.

A number of other equities analysts have also commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research report on Monday, December 29th. Citigroup lowered their target price on shares of Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Raymond James Financial set a $3.00 target price on shares of Health Catalyst in a research report on Friday. Canaccord Genuity Group set a $2.00 price target on Health Catalyst in a research report on Friday. Finally, Cantor Fitzgerald dropped their price objective on Health Catalyst from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $3.38.

Health Catalyst Stock Down 23.9%

Shares of HCAT traded down $0.43 during trading hours on Friday, hitting $1.36. 1,183,338 shares of the company were exchanged, compared to its average volume of 811,744. The firm’s 50 day moving average is $2.07 and its 200-day moving average is $2.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. Health Catalyst has a 52 week low of $1.20 and a 52 week high of $5.06. The company has a market cap of $96.33 million, a PE ratio of -0.85 and a beta of 1.76.

Institutional Investors Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of HCAT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after buying an additional 2,624 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its stake in Health Catalyst by 9.7% in the second quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock valued at $162,000 after acquiring an additional 3,808 shares during the period. The Manufacturers Life Insurance Company increased its stake in Health Catalyst by 19.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after acquiring an additional 4,341 shares during the period. BNP Paribas Financial Markets raised its position in Health Catalyst by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock worth $47,000 after purchasing an additional 6,832 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in Health Catalyst by 6.5% during the fourth quarter. Invesco Ltd. now owns 118,591 shares of the company’s stock worth $283,000 after purchasing an additional 7,186 shares during the period. Institutional investors own 85.00% of the company’s stock.

Health Catalyst News Summary

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Full‑year strength: Health Catalyst reported FY2025 total revenue of $311.1M and Adjusted EBITDA of $41.4M; management framed 2026 as a year to position the business for long‑term success. GlobeNewswire release
• Positive Sentiment: Technical/analyst note: A Zacks piece highlights a potential technical bottom (hammer pattern) and improving earnings‑estimate revisions that could support a near‑term recovery if fundamentals stabilize. Zacks: May find a bottom
• Neutral Sentiment: Earnings call available: The full Q4 earnings call transcript is now public — useful for hearing management’s commentary on margin drivers, backlog, and product/service adoption before placing trades. Seeking Alpha transcript
• Neutral Sentiment: Industry context/analysis: Coverage notes the firm’s longer‑term story is shifting after a difficult 2025 for health‑tech names; watch healthcare IT spending trends and durable client wins. Yahoo Finance analysis
• Negative Sentiment: Quarterly profit miss: Q4 EPS of $0.08 missed Zacks/consensus (roughly $0.09–$0.10), though revenue of ~$74.7M was roughly in line with expectations. Zacks: Lags Q4 estimates
• Negative Sentiment: Weak near‑term guidance: Management set Q1 2026 revenue guidance of $68.0M–$70.0M, well below the consensus (~$74M), which is the primary driver of the pullback — investors typically punish visible downward guidance. MarketBeat earnings summary
• Negative Sentiment: Profitability/returns remain weak: Q4 showed a negative net margin (~‑34%) and negative ROE, underscoring ongoing margin pressure even as revenue grows. MarketBeat metrics

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.